1)

A crystallisation process comprising:

10)

solution of a Carbomer.

30

- 6) A crystallisation process as claimed in any preceding claim-wherein the substance to be crystallised is a drug substance or a carrier for drug particles, suitable for use in an inhaled pharmaceutical composition. 5 A crystallisation process as claimed in any 7) preceding_claim-wherein the substance to be crystallised is lactose, lactose monohydrate, salbutamol sulphate or ipratropium bromide. 8) A crystallisation process as claimed in any-preceding-claim, wherein the 10 crystals are harvested by means bf collection by filtration. 9) A crystallisation process as claimed in any-preceding-claim, wherein the ξħ process comprises: ţħ. ļ 15 a) dissolving the substance to be crystallised in an aqueous solution ļΨ of a medium wherein the viscosity of the medium is pH-dependent; ļ± ļ h adjusting the pH/of/the medium until a gel with an apparent b) ķ viscosity in the range 25 to 90 Pa.s at a shear rate of 1s-1 is ΓIJ 20 reached: C) allowing crystal growth; d) adjusting the plf of the medium until a fluid with an apparent 25 viscosity less than 25 Pa.s at a shear rate of 1s-1 is reached; and harvesting the/crystals. e)
 - A crystallisation process as claimed in claim 1 or 2 wherein the substance to be crystallised is fluticasone propionate or salmeterol xinafoate

A process as claimed in claim 9 wherein the medium is an aqueous

- Lactose monohydrate, crystals obtained according to the process as 12) claimed in any preceding claim.
- Lactose monohydrate crystals as claimed in claim 12 for use in powder 13) formulations for inhaled use.
 - Salbutamol sulphate, oxitropium bromide or ipratropium bromide crystals obtained according to the process as claimed in any of claims 1 to 10.
- 10 Fluticasone propionate or salmeterol xinafoate crystals obtained according to the process as claimed in claim 1 or 2.
 - Salbutamol sulphate, oxitropium bromide or ipratropium bromide crystals 16) as claimed in claim 14 for use in powder formulations for inhaled use.
 - 17) Fluticasone propionate or salmeterol xinafoate crystals as claimed in claim 15 for use in powder formulations for inhaled use.
 - A pharmaceutical formulation for adm/nistration by inhalation comprising 18) lactose monohydrate crystals as claimed in claim 12 and/or salbutamol sulphate or ipratropium bromide crystals_as-elaimed in claim 14:

A pharmaceutical formulation for administration by inhalation comprising lactose monohydrate crystals as claimed in claim 12 and/or fluticasone propionate or salmeterol xinafdate crystals_as_claimed-in-claim_15.

15

20

25

5